Levodopa

Treats OFF episodes. Sold as Larodopa, Dopar, Bendopa, Inbrija. Every FDA application for this active ingredient.

As of Nov 13, 2026, FDA lists 4 applications for Levodopa (sold as Larodopa, Dopar, Bendopa and others), first approved Jun 4, 1970, with 1 new use approved and 0 published complete response letters.

First approved: Jun 4, 1970
Applications: 4
New uses approved: 1
Complete response letters: 0
Medicare spending, 2024: $27.7M

Medicare Spending

CMS Part D and Part B, 2024, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2024	Change	Beneficiaries
Inbrija	Part D	$27.7M	+2%	2,431

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Jun 4, 1970	LarodopaNDA 16912 · New molecular entity	Roche	24	Discontinued
Jun 4, 1970	DoparNDA 16913 · New formulation or manufacturer	Shire	13	Discontinued
Dec 21, 2018	InbrijaNDA 209184 · New dosage form	Merz	5	Marketed
—	BendopaNDA 16948	Valeant Pharm Intl	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA